GU Cancers 2023 | PARP inhibitors plus novel endocrine agents for patients with metastatic prostate cancer

Silke Gillessen, MD, Oncological Institute of Southern Switzerland, Bellinzona, Switzerland, discusses the use of PARP inhibitors in combination with novel endocrine agents in the first-line setting for patients with metastatic prostate cancer. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.